Management of chronic pain syndromes: Issues and interventions

Pain Medicine

Volumn 6, Issue SUPPL. 1, 2005, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; BACLOFEN; CITALOPRAM; CLONAZEPAM; DESIPRAMINE; DEXTROMETHORPHAN; DICLOFENAC; DULOXETINE; ETIRACETAM; FLURBIPROFEN; GABAPENTIN; IMIPRAMINE; INDOMETACIN; KETAMINE; KETOROLAC; LAMOTRIGINE; LIDOCAINE; MELOXICAM; MEXILETINE; NORTRIPTYLINE; PAROXETINE; PIROXICAM; SULINDAC; TENOXICAM; TOPIRAMATE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE; ZONISAMIDE;

ALLERGIC REACTION; ANOREXIA; ARTHRITIS; ASTHENIA; CHRONIC PAIN; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; HEADACHE; HEART DISEASE; HUMAN; LOW BACK PAIN; NAUSEA; NOCICEPTIVE STIMULATION; ORTHOSTATIC HYPERTENSION; OSTEOARTHRITIS; POLYPHARMACY; REVIEW; SEDATION; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; SPINE FUSION; TACHYCARDIA; THOUGHT DISORDER; WEIGHT GAIN;

CHRONIC DISEASE; HUMANS; PAIN; PALLIATIVE CARE; SYNDROME;

EID: 28544444992     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2005.00054.x     Document Type: Review

References (101)

1. Verhaak PF, Kerssens JJ, Dekker J, Sorbi MJ, Bensing JM. Prevalence of chronic benign pain disorder among adults: A review of the literature. Pain 1998;77:231-9.
2. Aronoff GM, Gallagher RM, Feldman JB. Biopsychosocial evaluation and treatment of chronic pain. In: Raj PP, ed. Practical Management of Pain. 3rd edition. St. Louis, MO: Mosby, Inc.; 2000:156-68.
3. Prevalence of disabilities and associated health conditions among adults-United States, 1999. MMWR Morb Mortal Wkly Rep 2001;50:120-5.
4. Prevalence of self-reported arthritis or chronic joint symptoms among adults-United States, 2001. MMWR Morb Mortal Wkly Rep 2002;51:948-50.
5. Boden SD, Dreyer SJ, Levy HI. Management of low back pain. Current assessment and formulation of a blueprint for the health care delivery system of the future. Phys Med Rehabil Clin N Am 1998;9:419-33,ix.
6. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003;81:646-56.
7. Melzack R. Psychological aspects of pain. Implications for neural blockade. In: Cousins MJ, Bridenbaugh PO, eds. Neural Blockade in Clinical Anesthesia and Management of Pain. 3rd edition. St. Louis, MO: Lippincott-Raven; 1998:781-92.
8. Loeser JD, Turk DC. Multidisciplinary pain management. In: Loeser JD, Butler SH, Chapman CR, Turk DC, eds. Bonica's Management of Pain. 3rd edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:2069-79.
9. Scholz J, Woolf CJ. Can we conquer pain? Nat Neurosci 2002;5(suppl):1062-7.
10. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001;413:203-10.
11. Woolf CJ, Salter MW. Neuronal plasticity: Increasing the gain in pain. Science 2000;288:1765-9.
12. Woolf CJ, Decosterd I. Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients. Pain 1999;6(suppl):S141-7.
13. Max MB, Schafer SC, Culnane M, et al. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988;38:1427-32.
14. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999;159:1931-7.
15. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326:1250-6.
16. Galer BS, Gammaitoni A, Alvarez NA. Pain. In: Dale DC, Federmen DD, eds. ACP Medicine (Scientific American Medicine). New York: WebMD, Inc.; 2002:1-27.
17. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain 1999;83:389-400.
18. Strasser F, Driver LC, Burton AW. Update on adjuvant medications for chronic nonmalignant pain. Pain Pract 2003;3:282-97.
19. Raskin P, Donofrio PD, Rosenthal NR, et al. Topiramate vs placebo in painful diabetic neuropathy: Analgesic and metabolic effects. Neurology 2004;63:865-73.
20. Backonja MM. Use of anticonvulsants for treatment of neuropathic pain. Neurology 2002;59:S14-7.
21. Oskarsson P, Ljunggren JG, Lins PE. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group. Diabetes Care 1997;20:1594-7.
22. Physician's Desk Reference. 54th edition. Montvale NJ: Medical Economics Company, Inc; 2000.
23. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: Diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003;60:1524-34.
24. Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: A review of the literature. J Clin Pharmacol 2003;43:111-7.
25. Argoff CE, Gimbel J, Hale M, et al. Lidocaine patch 5% significantly improves pain intensity and pain relief in the treatment of low back pain, poster 171. 65th Annual Assembly of the American Academy of Physical Medicine and Rehabilitation. Phoenix, Arizona; 2004.
26. Gammaitoni AR, Galer BS, Onawola R, Jensen MP, Argoff CE. Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: Results of a pilot 2-week, open-label study using the Neuropathic Pain Scale. Curr Med Res Opin 2004;20(suppl 2):13-9.
27. Galer BS, Sheldon E, Patel N, et al. Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritis. Curr Med Res Opin 2004;20:1455-8.
28. Costigan M, Woolf CJ. Pain: Molecular mechanisms. J Pain 2000;1:35-44.
29. Woolf CJ, Costigan M. Transcriptional and post-translational plasticity and the generation of inflammatory pain. Proc Natl Acad Sci USA 1999;96:7723-30.
30. Salvemini D. Regulation of cyclooxygenase enzymes by nitric oxide. Cell Mol Life Sci 1997;53:576-82.
31. Vane JR, Mitchell JA, Appleton I, et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 1994;91:2046-50.
32. Wong CS, Hsu MM, Chou R, Chou YY, Tung CS. Intrathecal cyclooxygenase inhibitor administration attenuates morphine antinociceptive tolerance in rats. Br J Anaesth 2000;85:747-51.
33. Samad TA, Moore KA, Sapirstein A, et al. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001;410:471-5.
34. Ma W, Eisenach JC. Cyclooxygenase 2 in infiltrating inflammatory cells in injured nerve is universally up-regulated following various types of peripheral nerve injury. Neuroscience 2003;121:691-704.
35. Gan TJ, Woolf C, Brennan TJ, Kehlet H, Mekhail N. Unraveling the mechanisms and clinical consequences of pain: Recent discoveries and the implications for pain management: A case-based interactive forum. Available at: http://www. medscape.com/viewprogram/2441_pnt (accessed January 18, 2005).
36. Carlsson KC, Hoem NO, Moberg ER, Mathisen LC. Analgesic effect of dextromethorphan in neuropathic pain. Acta Anaesthesiol Scand 2004;48:328-36.
37. Fitzgibbon EJ, Viola R. Parenteral ketamine as an analgesic adjuvant for severe pain: Development and retrospective audit of a protocol for a palliative care unit. J Palliat Med 2005;8:49-57.
38. Correll GE, Maleki J, Gracely EJ, Muir JJ, Harbut RE. Subanesthetic ketamine infusion therapy: A retrospective analysis of a novel therapeutic approach to complex regional pain syndrome. Pain Med 2004;5:263-75.
39. Gammaitoni A, Gallagher RM, Welz-Bosna M. Topical ketamine gel: Possible role in treating neuropathic pain. Pain Med 2000;1:97-100.
40. Nitu AN, Wallihan R, Skljarevski V, Ramadan NM. Emerging trends in the pharmacotherapy of chronic pain. Expert Opin Investig Drugs 2003;12:545-59.
41. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995;44:423-33.
42. Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain 2002;18:S3-13.
43. Brown SC, Glass JM, Park DC. The relationship of pain and depression to cognitive function in rheumatoid arthritis patients. Pain 2002;96:279-84.
44. Wood PB. Stress and dopamine: Implications for the pathophysiology of chronic widespread pain. Med Hypotheses 2004;62:420-4.
45. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998;279:287-91.
46. Kirwin JL, Goren JL. Duloxetine: A dual serotonin-norepinephrine reuptake inhibitor for treatment of major depressive disorder. Pharmacotherapy 2005;25:396-410.
47. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study. Pain 2001;94:215-24.
48. Mellegers MA, Furlan AD, Mailis A. Gabapentin for neuropathic pain: Systematic review of controlled and uncontrolled literature. Clin J Pain 2001;17:284-95.
49. Wiffen P, Collins S, McQuay H, et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev 2000;CD001133.
50. Portenoy RK. Opioid therapy for chronic nonmalignant pain: A review of the critical issues. J Pain Symptom Manage 1996;11:203-17.
51. Bartleson JD. Evidence for and against the use of opioid analgesics for chronic nonmalignant low back pain: A review. Pain Med 2002;3:260-71.
52. Zenz M, Strumpf M, Tryba M. Long-term oral opioid therapy in patients with chronic nonmalignant pain. J Pain Symptom Manage 1992;7:69-77.
53. Rashiq S, Koller M, Haykowsky M, Jamieson K. The effect of opioid analgesia on exercise test performance in chronic low back pain. Pain 2003;106:119-25.
54. Moulin DE, Iezzi A, Amireh R, et al. Randomised trial of oral morphine for chronic non-cancer pain. Lancet 1996;347:143-7.
55. Jamison RN, Raymond SA, Slawsby EA, Nedeljkovic SS, Katz NP. Opioid therapy for chronic non-cancer back pain. A randomized prospective study. Spine 1998;23:2591-600.
56. Gallagher RM. Treatment planning in pain medicine. Integrating medical, physical, and behavioral therapies. Med Clin N Am 1999;83:823-49,viii.
57. Pasternak GW. The pharmacology of mu analgesics: From patients to genes. Neuroscientist 2001;7:220-31.
58. Lahdesmaki J, Scheinin M, Pertovaara A, Mansikka H. The alpha2A-adrenoceptor subtype is not involved in inflammatory hyperalgesia or morphine-induced antinociception. Eur J Pharmacol 2003;468:183-9.
59. Mansikka H, Zhou L, Donovan DM, Pertovaara A, Raja SN. The role of mu-opioid receptors in inflammatory hyperalgesia and alpha 2-adrenoceptor- mediated antihyperalgesia. Neuroscience 2002;113:339-49.
60. Royal M, Wienecke G, Movva V. (223) retrospective study of the efficacy of tizanidine in the treatment of chronic pain. Pain Med 2001;2:249.
61. Zuniga RE, Schlicht CR, Abram SE. Intrathecal baclofen is analgesic in patients with chronic pain. Anesthesiology 2000;92:876-80.
62. Krames ES. Interventional pain management. Appropriate when less invasive therapies fail to provide adequate analgesia. Med Clin N Am 1999;83:787-808,vii-viii.
63. Kaplan M, Derby RJ. Epidural corticosteroid injections: When, why, and how. J Musculoskel Med 1998;15:39-46.
64. Katz V, Schofferman J, Reynolds J. The sacroiliac joint: A potential cause of pain after lumbar fusion to the sacrum. J Spinal Disord Tech 2003;16:96-9.
65. Zink W, Graf BM. Local anesthetic myotoxicity. Reg Anesth Pain Med 2004;29:333-40.
66. Ohtori S, Takahashi K, Chiba T, et al. Phenotypic inflammation switch in rats shown by calcitonin gene-related peptide immunoreactive dorsal root ganglion neurons innervating the lumbar facet joints. Spine 2001;26:1009-13.
67. Weiler C, Nerlich AG, Bachmeier BE, Boos N. Expression and distribution of tumor necrosis factor alpha in human lumbar intervertebral discs: A study in surgical specimen and autopsy controls. Spine 2005;30:44-53; discussion 54.
68. Leclaire R, Fortin L, Lambert R, Bergeron YM, Rossignol M. Radiofrequency facet joint denervation in the treatment of low back pain: A placebo-controlled clinical trial to assess efficacy. Spine 2001;26:1411-6; discussion 1417.
69. van Kleef M, Barendse GA, Kessels A, et al. Randomized trial of radiofrequency lumbar facet denervation for chronic low back pain. Spine 1999;24:1937-42.
70. Lord SM, Barnsley L, Wallis BJ, McDonald GJ, Bogduk N. Percutaneous radio-frequency neurotomy for chronic cervical zygapophyseal-joint pain. N Engl J Med 1996;335:1721-6.
71. Tzaan WC, Tasker RR. Percutaneous radiofrequency facet rhizotomy-Experience with 118 procedures and reappraisal of its value. Can J Neurol Sci 2000;27:125-30.
72. Wang JC, Lin E, Brodke DS, Youssef JA. Epidural injections for the treatment of symptomatic lumbar herniated discs. J Spinal Disord Tech 2002;15:269-72.
73. Botwin KP, Gruber RD, Bouchlas CG, et al. Fluoroscopically guided lumbar transformational epidural steroid injections in degenerative lumbar stenosis: An outcome study. Am J Phys Med Rehabil 2002;81:898-905.
74. Houten JK, Errico TJ. Paraplegia after lumbosacral nerve root block: Report of three cases. Spine J 2002;2:70-5.
75. Freemont AJ, Peacock TE, Goupille P, et al. Nerve ingrowth into diseased intervertebral disc in chronic back pain. Lancet 1997;350:178-81.
76. Wetzel FT, McNally TA, Phillips FM. Intradiscal electrothermal therapy used to manage chronic discogenic low back pain: New directions and interventions. Spine 2002;27:2621-6.
77. Saal JA, Saal JS. Intradiscal electrothermal treatment for chronic discogenic low back pain: Prospective outcome study with a minimum 2-year follow-up. Spine 2002;27:966-73; discussion 973-64.
78. Mekhail N, Kapural L. Intradiscal thermal annuloplasty for discogenic pain: An outcome study. Pain Pract 2004;4:84-90.
79. Kim PS. Nucleoplasty. Tech Reg Anesth Pain Manage 2004;8:46-52.
80. Bono CM, Lee CK. Critical analysis of trends in fusion for degenerative disc disease over the past 20 years: Influence of technique on fusion rate and clinical outcome. Spine 2004;29:455-63; discussion Z455.
81. Zdeblick TA, Phillips FM. Interbody cage devices. Spine 2003;28:S2-7.
82. Christensen FB. Lumbar spinal fusion. Outcome in relation to surgical methods, choice of implant and postoperative rehabilitation. Acta Orthop Scand Suppl 2004;75:2-43.
83. Delamarter RB, Fribourg DM, Kanim LE, Bae H. ProDisc artificial total lumbar disc replacement: Introduction and early results from the United States clinical trial. Spine 2003;28:S167-75.
84. van Ooji A, Oner FC, Verbout AJ. Complications of artificial disc replacement: A report of 27 patients with the SB Charite disc. J Spinal Disord Tech 2003;16:369-83.
85. Liliang PC, Su TM, Liang CL, et al. Percutaneous vertebroplasty improves pain and physical functioning in elderly osteoporotic vertebral compression fracture patients. Gerontology 2005;51:34-9.
86. Diamond TH, Champion B, Clark WA. Management of acute osteoporotic vertebral fractures: A nonrandomized trial comparing percutaneous vertebroplasty with conservative therapy. Am J Med 2003;114:257-65.
87. Taylor RS, Van Buyten JP, Buchser E. Spinal cord stimulation for chronic back and leg pain and failed back surgery syndrome: A systematic review and analysis of prognostic factors. Spine 2005;30:152-60.
88. Gay ML. Spinal morphine in nonmalignant chronic pain: A retrospective study in 39 patients. Neuromodulation 2002;5:150-9.
89. Corrado PE, Varga CA, Concannon DM. Is intrathecal drug therapy an effective treatment for chronic pain? Am J Pain Manage 2005;15:33-7.
90. Harris S, Morley S, Barton SB. Role loss and emotional adjustment in chronic pain. Pain 2003;105:363-70.
91. Gallagher RM, Verma S. Mood and anxiety disorders in chronic pain. In: Dworkin R, Brieghtbart W, eds. Psychosocial and Psychiatric Aspects of Pain: A Handbook for Health Care Providers. Vol. 27. Seattle, WA: IASP Press; 2004:139-78.
92. Silver A, Haeney M, Vijayadurai P, et al. The role of fear of physical movement and activity in chronic fatigue syndrome. J Psychosom Res 2002;52:485-93.
93. Jordan KD, Mayer TG, Gatchel RJ. Should extended disability be an exclusion criterion for tertiary rehabilitation? Socioeconomic outcomes of early versus late functional restoration in compensation spinal disorders. Spine 1998;23:2110-6; discussion 2117.
94. de Lissovoy G, Brown RE, Halpern M, Hassenbusch SJ, Ross E. Cost-effectiveness of long-term intrathecal morphine therapy for pain associated with failed back surgery syndrome. Clin Ther 1997;19:96-112; discussion 184-15.
95. Loeser JD, Cousins MJ. Contemporary pain management. Med J Aust 1990;153:208-212,216.
96. Turk DC, Stacey BR. Multidisciplinary pain centers in the treatment of chronic back pain. In: Frymoyer JW, ed. The Adult Spine: Principles and Practice. Philadelphia, PA: Lippincott-Raven 1997:253-74.
97. Morley S, Eccleston C, Williams A. Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. Pain 1999;80:1-13.
98. Sanders SH, Harden RN, Benson SE, Vincente PJ. Clinical practice guidelines for chronic nonmalignant pain syndrome patients II: An evidence-based approach. J Back Musculoskeletal Rehabil 1999;13:47-58.
99. Flor H, Fydrich T, Turk DC. Efficacy of multidisciplinary pain treatment centers: A meta-analytic review. Pain 1992;49:221-30.
100. Turk DC. Clinical effectiveness and cost-effectiveness of treatments for patients with chronic pain. Clin J Pain 2002;18:355-65.
101. Guzman J, Esmail R, Karjalainen K, et al. Multidisciplinary rehabilitation for chronic low back pain: Systematic review. BMJ 2001;322:1511-6.